DK1242060T3 - Behandling af metastatisk sygdom - Google Patents
Behandling af metastatisk sygdomInfo
- Publication number
- DK1242060T3 DK1242060T3 DK00955687T DK00955687T DK1242060T3 DK 1242060 T3 DK1242060 T3 DK 1242060T3 DK 00955687 T DK00955687 T DK 00955687T DK 00955687 T DK00955687 T DK 00955687T DK 1242060 T3 DK1242060 T3 DK 1242060T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- metastatic disease
- compounds
- metastatic
- disease
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14925899P | 1999-08-17 | 1999-08-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1242060T3 true DK1242060T3 (da) | 2006-08-21 |
Family
ID=22529456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK00955687T DK1242060T3 (da) | 1999-08-17 | 2000-08-17 | Behandling af metastatisk sygdom |
Country Status (10)
Country | Link |
---|---|
EP (2) | EP1242060B1 (ja) |
JP (2) | JP2003516930A (ja) |
AT (1) | ATE324877T1 (ja) |
AU (1) | AU6784400A (ja) |
CA (1) | CA2380888A1 (ja) |
DE (1) | DE60027768T2 (ja) |
DK (1) | DK1242060T3 (ja) |
ES (1) | ES2261230T3 (ja) |
PT (1) | PT1242060E (ja) |
WO (1) | WO2001012172A1 (ja) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7192698B1 (en) | 1999-08-17 | 2007-03-20 | Purdue Research Foundation | EphA2 as a diagnostic target for metastatic cancer |
US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
CA2405299C (en) | 2000-03-31 | 2014-07-22 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
US7101976B1 (en) | 2000-09-12 | 2006-09-05 | Purdue Research Foundation | EphA2 monoclonal antibodies and methods of making and using same |
CA2369183A1 (en) * | 2001-01-23 | 2002-07-23 | Amsterdam Support Diagnostics B.V. | Means and methods for treatment evaluation |
EP1298221A1 (en) * | 2001-09-28 | 2003-04-02 | PrimaGen Holding B.V. | Means and methods for treatment evaluation |
EP1225233A3 (en) * | 2001-01-23 | 2003-01-08 | Amsterdam Support Diagnostics B.V. | Means and methods for treatment evaluation |
WO2003028634A2 (en) * | 2001-09-28 | 2003-04-10 | Purdue Research Foundation | Method of treatment using ligand-immunogen conjugates |
WO2003070883A2 (en) * | 2002-02-15 | 2003-08-28 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules. |
ATE530577T1 (de) * | 2002-05-10 | 2011-11-15 | Purdue Research Foundation | Epha2 agonistische monoklonale antikörper und deren anwendungsverfahren |
EP1519956B1 (en) * | 2002-05-10 | 2011-09-21 | Medimmune, Inc. | Epha2 monoclonal antibodies and methods of use thereof |
US7662770B2 (en) | 2002-05-23 | 2010-02-16 | Purdue Research Foundation | Low molecular weight protein tyrosine phosphatase (LMW-PTP) as a diagnostic and therapeutic target |
AU2004210463B2 (en) * | 2003-02-07 | 2009-07-16 | Ludwig Institute For Cancer Research Limited | Eph/ephrin mediated modulation of cell adhesion and tumour cell metastasis |
AU2003900541A0 (en) * | 2003-02-07 | 2003-02-20 | Ludwig Institute For Cancer Research | Modulation of cell adhesion and tumour cell metastasis |
JP2006524693A (ja) * | 2003-04-11 | 2006-11-02 | メディミューン,インコーポレーテッド | EphA2および非腫瘍性過増殖性細胞障害 |
WO2004092343A2 (en) * | 2003-04-11 | 2004-10-28 | Medimmune, Inc. | Epha2, hypoproliferative cell disorders and epithelial and endothelial reconstitution |
JP4838720B2 (ja) | 2003-05-13 | 2011-12-14 | ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド | 転移および転移がもたらす骨格関連現象を調節する方法 |
WO2005016381A2 (en) * | 2003-07-21 | 2005-02-24 | Medimmune, Inc. | Combination therapy for the treatment and prevention of cancer using epha2, pcdgf, and haah |
JP4860477B2 (ja) * | 2003-11-20 | 2012-01-25 | メディミューン,エルエルシー | EphA2アゴニストモノクローナル抗体およびその使用法 |
EP1751289B1 (en) | 2004-05-18 | 2009-01-14 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
JP2008510007A (ja) | 2004-08-16 | 2008-04-03 | メディミューン,インコーポレーテッド | 抗体依存性細胞性細胞傷害活性が増強されたEph受容体Fc変異体 |
CN104059150B (zh) | 2005-02-04 | 2018-10-02 | 宏观基因有限公司 | 结合epha2的抗体及其使用方法 |
US8168164B2 (en) | 2006-02-03 | 2012-05-01 | Purdue Research Foundation | Targeted conjugates and radiation |
AU2007274738B2 (en) * | 2006-07-18 | 2013-11-28 | Sanofi-Aventis | Antagonist antibody against EphA2 for the treatment of cancer |
WO2008085557A2 (en) | 2006-09-12 | 2008-07-17 | Alphavax, Inc. | Alphavirus replicon particles encoding il- 12 as immunological adjuvants |
WO2008033966A2 (en) | 2006-09-12 | 2008-03-20 | Alphavax, Inc. | Alphavirus replicon particles matched to protein antigens as immunological adjuvants |
WO2008058035A1 (en) | 2006-11-03 | 2008-05-15 | Alphavax, Inc. | Alphavirus and alphavirus replicon particle formulations and methods |
JP5312333B2 (ja) * | 2007-08-30 | 2013-10-09 | 第一三共株式会社 | 抗epha2抗体 |
TW201116297A (en) | 2009-10-02 | 2011-05-16 | Sanofi Aventis | Antibodies that specifically bind to the EphA2 receptor |
JP5875054B2 (ja) * | 2013-02-13 | 2016-03-02 | 国立大学法人 東京大学 | がんの検査方法及び検査用キット |
JP6729917B2 (ja) * | 2016-08-19 | 2020-07-29 | 国立大学法人 東京大学 | EphA2 N末端フラグメント抗体 |
CA3111440A1 (en) | 2018-08-03 | 2020-02-06 | Uab Research Foundation | Methods and compositions for alphavirus vaccine |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69228300T2 (de) | 1991-08-22 | 1999-09-23 | Becton Dickinson And Co., Franklin Lakes | Methoden und zusammensetzungen zur krebstherapie und zur vorhersagbarkeit der reaktionen auf diese behandlung |
US5811098A (en) | 1992-11-24 | 1998-09-22 | Bristol-Myers Squibb Company | Antibodies to HER4, human receptor tyrosine kinase |
CA2103323A1 (en) * | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
US5587459A (en) | 1994-08-19 | 1996-12-24 | Regents Of The University Of Minnesota | Immunoconjugates comprising tyrosine kinase inhibitors |
ATE293989T1 (de) * | 1998-11-20 | 2005-05-15 | Genentech Inc | Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten |
-
2000
- 2000-08-17 EP EP00955687A patent/EP1242060B1/en not_active Revoked
- 2000-08-17 AT AT00955687T patent/ATE324877T1/de not_active IP Right Cessation
- 2000-08-17 PT PT00955687T patent/PT1242060E/pt unknown
- 2000-08-17 ES ES00955687T patent/ES2261230T3/es not_active Expired - Lifetime
- 2000-08-17 WO PCT/US2000/022670 patent/WO2001012172A1/en active IP Right Grant
- 2000-08-17 JP JP2001516518A patent/JP2003516930A/ja active Pending
- 2000-08-17 DK DK00955687T patent/DK1242060T3/da active
- 2000-08-17 DE DE60027768T patent/DE60027768T2/de not_active Revoked
- 2000-08-17 AU AU67844/00A patent/AU6784400A/en not_active Abandoned
- 2000-08-17 CA CA002380888A patent/CA2380888A1/en not_active Abandoned
- 2000-08-17 EP EP10010861A patent/EP2289940A3/en not_active Withdrawn
-
2007
- 2007-08-15 JP JP2007211840A patent/JP2007306938A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE60027768D1 (de) | 2006-06-08 |
CA2380888A1 (en) | 2001-02-22 |
PT1242060E (pt) | 2006-08-31 |
JP2003516930A (ja) | 2003-05-20 |
JP2007306938A (ja) | 2007-11-29 |
EP1242060A1 (en) | 2002-09-25 |
WO2001012172B1 (en) | 2001-08-16 |
DE60027768T2 (de) | 2007-04-05 |
EP1242060B1 (en) | 2006-05-03 |
EP2289940A3 (en) | 2011-09-21 |
ES2261230T3 (es) | 2006-11-16 |
EP1242060A4 (en) | 2003-09-24 |
AU6784400A (en) | 2001-03-13 |
ATE324877T1 (de) | 2006-06-15 |
EP2289940A2 (en) | 2011-03-02 |
WO2001012172A1 (en) | 2001-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK1242060T3 (da) | Behandling af metastatisk sygdom | |
TR200003514T2 (tr) | Pirol ikame edilmiş 2-indolinon protein kinaz inhibitörleri | |
EE05481B1 (et) | Kinasoliini derivaadid kasvajate raviks | |
BR9814361A (pt) | Inibição de quinase raf usando uréiasheterocìclicas substituìdas por arila eheteroarila | |
NO2010002I2 (no) | Toceranibfosfat. | |
BR0215360A (pt) | Derivados de indolina úteis como inibidores de proteìna quinase | |
BR0316229A (pt) | Métodos de tratamento de câncer e métodos relacionados | |
BRPI0007487B8 (pt) | difenil-uréias substituídas com w-carbóxi-arilas como inibidores de raf cinase | |
DE502004002571D1 (de) | Substituierte 3-pyrrolidin-indol-derivate | |
UY26981A1 (es) | Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona | |
DK1147089T3 (da) | Phenylphenanthridiner med PDE-IV-inhiberende virkning | |
SE9900100D0 (sv) | New compounds | |
WO2004100947A3 (en) | Novel chemical compounds | |
AU2005293821A1 (en) | N,N'-dithenylurea derivatives used in the form of kinase inhibitors | |
BR0209149A (pt) | Ftalazinonas | |
TR200200260T2 (tr) | N-desmetilzopiklonlarının üretim ve kullanım yöntemleri | |
TR200401316T4 (tr) | Proliferatif hastalıkları tedavi etmek için yöntemler ve bileşikler | |
BR0316296A (pt) | Compostos lapacone e seus métodos de uso | |
DE60033918D1 (de) | Polysubstituted 6-phenylphenanthridines mit pde-iv hemmender wirkung | |
ATE296809T1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
DE60228544D1 (de) | Triptolid-prodrugs zur krebstherapie | |
DK1268472T3 (da) | 3-aminopyrazolinhibitorer af cyclinafhængige kinaser | |
ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer | |
ATE281439T1 (de) | 3,4-dihydro-(1h)chinazolin-2-on-verbindungen als csbp/p38-kinase-inhibitoren | |
DE50309381D1 (de) | Neue pyrimidin-4,6-dicarbons urediamide zur selektiven inhibierung von kollagenasen |